World's Best Scientists 2026 revealed!
Hideaki Tahara

Hideaki Tahara

D-Index & Metrics

Immunology

D-Index
67
Citations
16937
World Ranking
2661
National Ranking
106

Hideaki Tahara publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Hideaki Tahara sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 226 publications — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Hideaki Tahara D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Hideaki Tahara sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 67 D-Index — 47th percentile

47% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Hideaki Tahara is affiliated with the University of Tokyo in Japan and has a research focus primarily in the fields of Medicine, Biochemistry, Genetics and Molecular Biology, and Immunology and Microbiology. Their work concentrates on oncology, molecular biology, and immunology, with specific attention to subfields such as pulmonary and respiratory medicine and genetics.

The scientist's research topics cover areas including immunotherapy and immune responses, immune cell function and interaction, peptidase inhibition and analysis, immune cells in cancer, chromatin remodeling and cancer, cancer immunotherapy and biomarkers, as well as virus-based gene therapy research.

Frequent publication venues for their work include Cancer Science, Immunotherapy, JTO Clinical and Research Reports, Cancer Immunology Immunotherapy, and Molecular Therapy - Oncolytics.

Hideaki Tahara has collaborated regularly with several co-authors, which include:

  • Yu Mizote
  • Takashi Akazawa
  • Keiichiro Honma
  • Tomoya Ekawa
  • Kei Kunimasa

Among the recent papers associated with their research are:

  • Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma (2021, Immunotherapy)
  • Conversion Surgery for Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor With Atezolizumab in Combination With Bevacizumab, Paclitaxel, and Carboplatin Treatment: A Case Report (2021, JTO Clinical and Research Reports)
  • The liposome of trehalose dimycolate extracted from M. bovis BCG induces antitumor immunity via the activation of dendritic cells and CD8+ T cells (2021, Cancer Immunology Immunotherapy)
  • Cancer-derived cholesterol sulfate is a key mediator to prevent tumor infiltration by effector T cells (2022, International Immunology)
  • Potent anti-tumor effects of receptor-retargeted syncytial oncolytic herpes simplex virus (2021, Molecular Therapy - Oncolytics)

Best Publications

  • Interleukin-17 promotes angiogenesis and tumor growth.

    Muneo Numasaki;Jun Ichi Fukushi;Mayumi Ono;Satwant K. Narula

  • Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production.

    C L Nastala;H D Edington;T G McKinney;H Tahara

  • Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis

    Hiroshi Oka;Hitoshi Shiozaki;Kenji Kobayashi;Masatoshi Inoue

  • Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.

    Michael B. Atkins;Michael J. Robertson;Michael Gordon;Michael T. Lotze

  • Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells

    Masahisa Jinushi;Shigeki Chiba;Hironori Yoshiyama;Kenkichi Masutomi

  • Viral vectors for gene therapy

    Paul D. Robbins;Hideaki Tahara;Steven C. Ghivizzani

  • Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo.

    Hideaki Tahara;Herbert J. Zeh;Walter J. Storkus;Itzhak Pappo

  • IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.

    Tadashi Osaki;Jean Marie Péron;Quan Cai;Haruki Okamura

  • Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector.

    H. Tahara;L. Zitvogel;W. J. Storkus;H. J. Zeh

  • Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12

    Yasuhiko Nishioka;Motohiro Hirao;Paul D. Robbins;Michael T. Lotze

  • Adenovirus-Mediated Transfer of siRNA against Survivin Induced Apoptosis and Attenuated Tumor Cell Growth in Vitro and in Vivo

    Hiroaki Uchida;Hiroaki Uchida;Toshihiro Tanaka;Katsunori Sasaki;Kazunori Kato

  • Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice.

    Robert M. Berman;Tadamichi Suzuki;Hideaki Tahara;Paul D. Robbins

  • Differential Antitumor Effects of Administration of Recombinant IL-18 or Recombinant IL-12 Are Mediated Primarily by Fas-Fas Ligand- and Perforin-Induced Tumor Apoptosis, Respectively

    Wataru Hashimoto;Tadashi Osaki;Tadashi Osaki;Haruki Okamura;Paul D. Robbins

  • Viral interleukin 10 (IL-10), the human herpes virus 4 cellular IL-10 homologue, induces local anergy to allogeneic and syngeneic tumors.

    Tadamichi Suzuki;Hideaki Tahara;Satwant Narula;Kevin W. Moore

  • Retrovirus-mediated transfer of viral IL-10 gene prolongs murine cardiac allograft survival

    Lihui Qin;Kenneth D. Chavin;Yaozhong Ding;Hideaki Tahara

  • Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors

    Hiroaki Shime;Misako Matsumoto;Hiroyuki Oshiumi;Shinya Tanaka

  • Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts.

    L Zitvogel;H Tahara;P D Robbins;W J Storkus

  • Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness.

    Takuya Takayama;Yasuhiko Nishioka;Lina Lu;Michael T. Lotze

  • CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: critical role in migration from the tumor site to draining lymph nodes.

    Motohiro Hirao;Nobuyuki Onai;Kazumasa Hiroishi;Simon C. Watkins

  • Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer.

    H Tahara;M T Lotze

Frequent Co-Authors

Michael T. Lotze
Michael T. Lotze University of Pittsburgh
Paul D. Robbins
Paul D. Robbins University of Minnesota
Walter J. Storkus
Walter J. Storkus University of Pittsburgh
Angus W. Thomson
Angus W. Thomson University of Pittsburgh
Masabumi Shibuya
Masabumi Shibuya Jobu University
Yusuke Nakamura
Yusuke Nakamura National Institutes of Biomedical Innovation, Health and Nutrition
Laurence Zitvogel
Laurence Zitvogel University of Paris-Saclay
Yoshihiro Hayakawa
Yoshihiro Hayakawa Aichi Institute of Technology
Haruki Okamura
Haruki Okamura Hyogo College of Medicine
Theresa L. Whiteside
Theresa L. Whiteside University of Pittsburgh

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related online degrees can open diverse career opportunities in healthcare and research. Nursing programs often provide a solid foundation in patient care and biological sciences, which complement immunology knowledge. One popular option is online absn programs for non nurses, designed for individuals transitioning into nursing without prior experience. These accelerated programs quickly prepare students for clinical roles.

Similarly, accelerated bsn programs for non nurses offer streamlined pathways to earn a Bachelor of Science in Nursing, often emphasizing hands-on experience and immunology concepts. For those looking at entry-level nursing roles, best easiest lpn programs to get into provide accessible routes toward becoming Licensed Practical Nurses, a practical step for building healthcare expertise.

Advanced practice roles also align well with immunology, especially nurse practitioners who engage in diagnosis and treatment. The easiest np program options can help streamline entry into this demanding but rewarding field. Ultimately, combining immunology studies with nursing credentials enhances career versatility in medical research, clinical practice, and public health.

Best Scientists Citing Hideaki Tahara

Trending Scientists

Recently Published Articles